ArticleClinical, cosmetic and investigational dermatology2025
Integrative Analysis Reveals a Key Role for CDKN1A in Impaired Wound Healing in Diabetic Patients.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Single-cell mapping of diabetic foot ulcers: mechanistic axes and therapeutic targets.Frontiers in medicine · 2026Review
- Multidimensional Regulatory Mechanisms and Targeted Therapeutic Strategies for Inhibited Keratinocyte Proliferation in Diabetic Wounds.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic foot ulcers (DFUs) are a common and severe complication of diabetes, often resulting in chronic non-healing wounds. This study aims to investigate the role of cyclin-dependent kinase inhibitor 1A (CDKN1A) in diabetic wound healing, focusing on its impact on cell proliferation and differentiation in DFUs. Methods: We utilized single-cell RNA sequencing (scRNA-seq) to analyze gene expression profiles from DFUs tissues, comparing healing and non-healing groups. Differential gene expression analysis was performed to identify key regulators of wound healing. Mendelian randomization (MR) was employed to explore the causal relationship between CDKN1A expression and metabolic dysfunction in DFUs. Transcription factor analysis was also conducted to identify potential upstream regulators of CDKN1A. Results: Our study confirmed that CDKN1A played a pivotal role in inhibiting cell proliferation and promoting premature differentiation in DFUs, which contributed to impaired wound healing. FOS was identified as a key transcription factor that upregulates CDKN1A in non-healing DFUs. MR analysis identified CDKN1A as being associated with metabolic changes, including the α-ketobutyrate/pyruvate ratio, leading to the impaired healing process in non-healing DFUs. Conclusion: These findings shed light on the molecular mechanisms underlying DFU healing, suggesting that targeting FOS and CDKN1A could offer novel therapeutic strategies for enhancing wound healing in diabetic patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.